Skip to content
Original
mp.weixin.qq.com·· 7 hours agoScore86

ESMO and New England Journal of Medicine Simultaneously Publish OptiTROP-Lung06: sac-TMT Plus Pembrolizumab Extends PFS

In brief

ESMO and the New England Journal of Medicine simultaneously published the OptiTROP-Lung06 results. The combination of sac-TMT and pembrolizumab reduced the risk of disease progression or death by 51%.

Source: mp.weixin.qq.com · mp.weixin.qq.com

#Clinical readout#Oncology#ADCs & conjugates#Immunotherapy
CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.